On March 4, 2026, Tenaya Therapeutics, Inc. entered a collaboration agreement with Alnylam Pharmaceuticals to research cardiovascular disease treatment, involving a $10 million upfront payment and potential milestone payments up to $1.13 billion. This event is significant as it opens up new research avenues and financial opportunities for Tenaya.